SCHEMBL2398464

SCHEMBL2398464

Cc1nc2c(s1)C(=O)C=C(NCC1CCC(CNC3=CC(=O)c4sc(C)nc4C3=O)CC1)C2=O

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.63
CDC25B P30305 1/20 0.63
CDC25C P30307 1/20 0.63
CDK4 P11802 9/20 0.54
KMT5A Q9NQR1 2/20 0.54
MEN1 O00255 1/20 0.54
THRB P10828 1/20 0.54
CCND1 P24385 1/20 0.54
BLM P54132 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
CHRM4 P08173 1/20 0.33
BRD4 O60885 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
LRRK2 Q5S007 1/20 0.32
PI4KB Q9UBF8 2/20 0.31
CA2 P00918 1/20 0.31
STAT3 P40763 1/20 0.31
NPY5R Q15761 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1917649 0.80 CDC25A (0.76) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL3809294 0.80 CDC25A (0.76) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL2401021 0.78 CDC25A (0.66) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL2400497 0.77 CDC25A (0.72) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL1917819 0.77 CDC25A (1.00) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL2401631 0.77 CDC25A (0.85) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL3815257 0.77 CDC25A (0.67) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL1918022 0.77 CDC25A (0.57) CDC25ACDC25BCDC25CCDK4KMT5A
SCHEMBL1917528 0.76 CDC25A (0.70) CDC25ACDC25BCDC25CCDK4KMT5A
Hydrochloric Acid SCHEMBL4209583 0.76 CDC25A (0.97) CDC25ACDC25BCDC25CCDK4KMT5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed
EP-1831209-A2 CDC25 PHOSPHATASE INHIBITORS Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) 2007-09-12 EP disclosed
WO-2006067311-A2 CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.